Free tool
FAERS Monitor: Norpramin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 014399 or its brand name (Norpramin, Desipramine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
279
Serious
185
66% of reports
Hospitalization
88
Death reported
27
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective29
- fatigue22
- drug hypersensitivity17
- nausea17
- headache16
- dyspnoea15
- toxicity to various agents15
- off label use14
- confusional state13
- dizziness12
- vomiting12
- depression11
- gastrooesophageal reflux disease11
- anxiety10
- fall10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 11 |
| 2006 | 9 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 8 |
| 2010 | 12 |
| 2011 | 18 |
| 2012 | 16 |
| 2013 | 6 |
| 2014 | 11 |
| 2015 | 15 |
| 2016 | 17 |
| 2017 | 22 |
| 2018 | 16 |
| 2019 | 15 |
| 2020 | 12 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 10 |
| 2024 | 15 |
| 2025 | 20 |
| 2026 | 15 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,880 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gastrooesophageal reflux diseaseSignal | 11 | 10.3 | 5.8 | 84 |
| toxicity to various agentsSignal | 15 | 6.7 | 4.1 | 68 |
| drug hypersensitivitySignal | 17 | 6.6 | 4.2 | 76 |
| confusional stateSignal | 13 | 6.1 | 3.6 | 50 |
| depressionSignal | 11 | 3.6 | 2.0 | 19 |
| anxietySignal | 10 | 2.6 | 1.4 | 9 |
| fallSignal | 10 | 2.3 | 1.2 | 6 |
| fatigueSignal | 22 | 2.1 | 1.4 | 13 |
| dyspnoea | 15 | 2.0 | 1.2 | 7 |
| vomiting | 12 | 1.9 | 1.1 | 5 |
| headache | 16 | 1.9 | 1.2 | 6 |
| dizziness | 12 | 1.8 | 1.0 | 4 |
| drug ineffective | 29 | 1.7 | 1.2 | 7 |
| nausea | 17 | 1.6 | 1.0 | 4 |
| off label use | 14 | 1.2 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.